Market Cap ₹1080 Cr.
Stock P/E 26.1
P/B 3.5
Current Price ₹487.1
Book Value ₹ 138.4
Face Value 2
52W High ₹621.4
Dividend Yield 0.41%
52W Low ₹ 365
Vimta Labs Ltd provides contract research and testing services in India and internationally. It offers laboratory, meals and water testing and evaluation, preclinical and clinical studies, biological molecule structural and environmental assessment, functional analysis and clinical reference laboratory offerings. The business enterprise serves pharmaceutical, biopharmaceutical, food, client goods, digital, electrical, agrochemical, healthcare, medical device, and various different industries. Vimta Labs Ltd was based in 1984 and is headquartered in Hyderabad, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 75 | 67 | 74 | 79 | 80 | 77 | 82 | 83 | 73 | 82 |
| Other Income | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Total Income | 76 | 68 | 75 | 80 | 81 | 79 | 82 | 84 | 75 | 83 |
| Total Expenditure | 56 | 47 | 51 | 55 | 54 | 56 | 58 | 59 | 58 | 60 |
| Operating Profit | 20 | 21 | 23 | 25 | 26 | 23 | 25 | 25 | 18 | 23 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 |
| Exceptional Income / Expenses | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 13 | 15 | 16 | 17 | 18 | 14 | 17 | 16 | 8 | 14 |
| Provision for Tax | 3 | 4 | 4 | 5 | 5 | 4 | 4 | 4 | 2 | 3 |
| Profit After Tax | 10 | 12 | 12 | 12 | 13 | 10 | 13 | 12 | 6 | 10 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 10 | 12 | 12 | 12 | 13 | 10 | 13 | 12 | 6 | 10 |
| Adjusted Earnings Per Share | 4.4 | 5.3 | 5.4 | 5.4 | 6 | 4.6 | 5.7 | 5.5 | 2.9 | 4.6 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|
| Net Sales | 181 | 211 | 278 | 318 | 320 |
| Other Income | 3 | 1 | 1 | 3 | 5 |
| Total Income | 184 | 212 | 280 | 322 | 324 |
| Total Expenditure | 151 | 158 | 198 | 223 | 235 |
| Operating Profit | 33 | 54 | 82 | 98 | 91 |
| Interest | 4 | 2 | 1 | 3 | 2 |
| Depreciation | 21 | 23 | 23 | 31 | 34 |
| Exceptional Income / Expenses | 0 | 0 | -1 | 0 | 0 |
| Profit Before Tax | 8 | 29 | 56 | 65 | 55 |
| Provision for Tax | 1 | 7 | 14 | 17 | 13 |
| Profit After Tax | 7 | 21 | 41 | 48 | 41 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 7 | 21 | 41 | 48 | 41 |
| Adjusted Earnings Per Share | 3.1 | 9.7 | 18.7 | 21.8 | 18.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 14% | 21% | 0% | 0% |
| Operating Profit CAGR | 20% | 44% | 0% | 0% |
| PAT CAGR | 17% | 90% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 25% | 24% | 22% | 16% |
| ROE Average | 19% | 17% | 14% | 14% |
| ROCE Average | 25% | 21% | 17% | 17% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Shareholder's Funds | 173 | 194 | 234 | 282 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 5 | 14 | 13 | 10 |
| Other Non-Current Liabilities | 9 | 11 | 11 | 9 |
| Total Current Liabilities | 58 | 54 | 48 | 57 |
| Total Liabilities | 245 | 273 | 305 | 358 |
| Fixed Assets | 138 | 135 | 169 | 175 |
| Other Non-Current Assets | 11 | 28 | 12 | 20 |
| Total Current Assets | 96 | 111 | 124 | 164 |
| Total Assets | 245 | 273 | 305 | 358 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 3 | 6 | 6 | 11 |
| Cash Flow from Operating Activities | 24 | 37 | 59 | 88 |
| Cash Flow from Investing Activities | -21 | -32 | -38 | -57 |
| Cash Flow from Financing Activities | -1 | -5 | -17 | -11 |
| Net Cash Inflow / Outflow | 3 | 1 | 5 | 20 |
| Closing Cash & Cash Equivalent | 6 | 6 | 11 | 31 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.1 | 9.68 | 18.69 | 21.77 |
| CEPS(Rs) | 12.56 | 20.12 | 29.24 | 35.65 |
| DPS(Rs) | 0 | 2 | 2 | 2 |
| Book NAV/Share(Rs) | 78.19 | 87.92 | 104.52 | 124.46 |
| Core EBITDA Margin(%) | 16.57 | 25.14 | 28.85 | 29.83 |
| EBIT Margin(%) | 6.66 | 14.58 | 20.55 | 21.26 |
| Pre Tax Margin(%) | 4.58 | 13.55 | 20.01 | 20.43 |
| PAT Margin (%) | 3.79 | 10.16 | 14.85 | 15.14 |
| Cash Profit Margin (%) | 15.37 | 21.11 | 23.24 | 24.79 |
| ROA(%) | 2.79 | 8.25 | 14.29 | 14.53 |
| ROE(%) | 3.96 | 11.66 | 19.43 | 19.02 |
| ROCE(%) | 5.84 | 14.25 | 23.92 | 24.59 |
| Receivable days | 116.83 | 113.74 | 98.63 | 90 |
| Inventory Days | 34.6 | 27.52 | 20.99 | 22.94 |
| Payable days | 0 | 1549.17 | 0 | 0 |
| PER(x) | 19.14 | 16.63 | 16.86 | 14.44 |
| Price/Book(x) | 0.76 | 1.83 | 3.01 | 2.52 |
| Dividend Yield(%) | 0 | 1.24 | 0.63 | 0.64 |
| EV/Net Sales(x) | 0.87 | 1.8 | 2.53 | 2.11 |
| EV/Core EBITDA(x) | 4.78 | 7.06 | 8.62 | 6.82 |
| Net Sales Growth(%) | 0 | 16.58 | 32.09 | 14.34 |
| EBIT Growth(%) | 0 | 155.16 | 86.22 | 18.29 |
| PAT Growth(%) | 0 | 212.71 | 93.09 | 16.55 |
| EPS Growth(%) | 0 | 212.71 | 93.09 | 16.45 |
| Debt/Equity(x) | 0.19 | 0.16 | 0.08 | 0.05 |
| Current Ratio(x) | 1.67 | 2.05 | 2.6 | 2.86 |
| Quick Ratio(x) | 1.37 | 1.78 | 2.24 | 2.46 |
| Interest Cover(x) | 3.2 | 14.16 | 38.17 | 25.57 |
| Total Debt/Mcap(x) | 0.25 | 0.09 | 0.03 | 0.02 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.46 | 37.46 | 37.46 | 37.46 | 37.25 | 37.24 | 37.23 | 37.01 | 36.98 | 36.92 |
| FII | 0.19 | 0.36 | 0.35 | 0.49 | 2.28 | 2.25 | 2.72 | 2.74 | 2.88 | 5.13 |
| DII | 1.91 | 1.95 | 2.01 | 2.04 | 2.13 | 2.14 | 2.13 | 1.5 | 1.49 | 1.5 |
| Public | 60.44 | 60.22 | 60.18 | 60.02 | 58.34 | 58.38 | 57.92 | 58.75 | 58.66 | 56.45 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.83 | 0.83 | 0.83 | 0.83 | 0.82 | 0.82 | 0.82 | 0.82 | 0.82 | 0.82 |
| FII | 0 | 0.01 | 0.01 | 0.01 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.11 |
| DII | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.03 | 0.03 | 0.03 |
| Public | 1.34 | 1.33 | 1.33 | 1.33 | 1.29 | 1.29 | 1.28 | 1.3 | 1.3 | 1.25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.21 | 2.21 | 2.21 | 2.21 | 2.21 | 2.21 | 2.21 | 2.21 | 2.22 | 2.22 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
